Evaluation of the efficiency and safety of anaferon (pediatric formulation) in the treatment of chickenpox in children.
Addition of anaferon (pediatric formulation) to the therapy of chickenpox patients led to more rapid disappearance of the main symptoms and alleviated the course of the disease. The safety of the preparation is confirmed by the absence of undesirable events and stability of laboratory indexes against the background of therapy.
Timchenko
V N
VN
Department of Infection Diseases in Children, Department of Clinical Pharmacology, St. Petersburg State Pediatric Medical Academy, Children's Polyclinic No.71, St. Petersburg.
Pavlova
E B
EB
Chernova
T M
TM
Bannova
S L
SL
Savel'eva
T I
TI
Tarasov
S A
SA
Kachanova
M V
MV
Siver'yanova
M A
MA
D000293:Adolescent; D000906:Antibodies / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002644:Chickenpox / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007369:Interferon Inducers / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome
D000906:Antibodies; D000998:Antiviral Agents; D007369:Interferon Inducers; C547732:anaferon